2024年，新城市实现营业收入1.99亿元，同比下降31.79%；归属于上市公司股东的净利润为-1.65亿 元，上年同期为-5236.21万元，亏损扩大；归属于上市公司股东的扣非净利润为-7101.57万元，上年同 期为1154.03万元；经营活动产生的现金流量净额为915.02万元，上年同期为17.43万元。 2025年1-9月，公司实现营业收入1.06亿元，同比下降36.52%；归属于上市公司股东的净利润 为-1,971.84万元，上年同期为-13,197.67万元；归属于上市公司股东的扣除非经常性损益的净利润 为-3,977.29万元，上年同期为-3,434.30万元；经营活动产生的现金流量净额为-2,149.27万元，同比增长 1.34%。 中国经济网北京11月21日讯 新城市（300778.SZ）昨日晚间披露《关于控股股东减持股份预披露公 告》。 根据公告，公司控股股东深圳市远思实业有限责任公司（以下简称"远思实业"）计划自公告披露之 日起15个交易日之后的3个月内（即2025年12月12日起至2026年3月11日止）以集中竞价方式或大宗交易 方式减持公司股份总数不超过6,012,450股（占公司目 ...

Core Viewpoint - The company, Inry Media (引力传媒), is facing challenges with its financial performance, including a history of losses and recent management share reductions, which may indicate a lack of confidence in future growth prospects [2][3]. Financial Performance - Since its listing in 2015, Inry Media has achieved a total revenue of 40.762 billion yuan, with cumulative net losses of 195 million yuan and 390 million yuan for net profit and net profit excluding non-recurring items, respectively [2]. - The company has not distributed dividends for seven consecutive years since 2018 [2]. - For the first half of 2025, Inry Media reported total revenue of 4.542 billion yuan, a year-on-year increase of 53.84%, while the net profit attributable to shareholders decreased by 10.76% to 15.9317 million yuan [2]. Shareholder Activity - The actual controllers of Inry Media, Luo Yanjie and Jiang Li, have repeatedly reduced their holdings in the company, collectively cashing out approximately 664 million yuan [2]. - In early 2025, Luo Yanjie transferred 5.029% of the company's shares for 194 million yuan, while Jiang Li transferred 5.6% of the shares for 162 million yuan in October 2024 [3]. - Historical reductions include Jiang Li's cashing out of 78.1123 million yuan from December 2019 to June 2020 and Luo Yanjie's cashing out of 114 million yuan from March to September 2020 [3].

Core Viewpoint - The actual controller of Botao Bio (688767.SH), Yu Xiuping, announced a share reduction plan due to personal funding needs, intending to reduce up to 4,479,999 shares, which is no more than 3% of the total shares [1][2]. Summary by Relevant Sections Share Reduction Plan - Yu Xiuping plans to reduce shares through block trading or centralized bidding, with a maximum of 1,493,333 shares (1% of total shares) via centralized bidding and 2,986,666 shares (2% of total shares) via block trading [1][2]. - The reduction period is set for three months starting from 15 trading days after the announcement [1][2]. Shareholding Information - As of the announcement date, Yu Xiuping holds 24,953,600 shares, accounting for 16.71% of the total shares [2]. - The shares intended for reduction were acquired before the IPO and through rights distribution [2]. Financial Performance - Botao Bio's initial public offering raised a total of 921 million yuan, with a net amount of 829 million yuan after expenses, which were 91.96 million yuan [3]. - The net profits attributable to shareholders from 2021 to 2024 were 834 million yuan, 774 million yuan, 107 million yuan, and 170 million yuan, respectively [3].

Core Viewpoint - The announcement details a share reduction plan by Yuan Liping, a significant shareholder of Kangtai Biological, which will not affect the company's control or governance structure [1][3]. Shareholder Changes - Yuan Liping plans to reduce her holdings by up to 11,160,000 shares, representing 1.00% of the total share capital, within three months from the announcement date [1]. - As of July 24, 2025, Yuan Liping has already reduced her holdings by 4,307,904 shares, which is 0.38% of the total share capital, realizing approximately 74.35 million yuan [1]. - Prior to this reduction, Yuan Liping held 137,331,675 shares (19.61% of total capital), and after the reduction, she holds 197,422,776 shares (17.68% of total capital) [1]. Control and Governance - The reduction in shares will not lead to a change in the company's control or significantly impact its governance structure [3]. - Before the reduction, Yuan Liping and other associated parties held a combined total of 339,099,830 shares (48.42% of total capital), which decreased to 530,121,967 shares (47.46% of total capital) after the reduction [2]. Fundraising Activities - Kangtai Biological raised a total of 3 billion yuan through a private placement of shares in 2020, with a net amount of approximately 2.985 billion yuan after expenses [3]. - In 2021, the company issued 20 million convertible bonds, raising a total of 2 billion yuan, with a net amount of approximately 1.98966 billion yuan after expenses [4]. - Over the past five years, Kangtai Biological has cumulatively raised 5 billion yuan [5].

Core Viewpoint - Central to the news is the announcement by Zhongya Co., Ltd. regarding the planned reduction of shares by its chairman and several shareholders, marking the third such announcement in 2025, amidst a backdrop of declining profits and stock price fluctuations [1][4]. Group 1: Shareholding Changes - The chairman and several shareholders plan to reduce their holdings by up to 5,108,600 shares, representing 1.27% of the company's total share capital after excluding repurchased shares [2]. - Specific plans include the chairman reducing up to 1,500,000 shares (0.3720%), and similar reductions by other shareholders, including Xu Manhua and Hangzhou Fupai [2][3]. - This marks the third pre-disclosure of share reduction by Zhongya Co., Ltd. in 2025, following a previous announcement in February where only a fraction of the planned reduction was executed [4]. Group 2: Financial Performance - Zhongya Co., Ltd. has experienced a continuous decline in net profit over the past three years, with figures of 133 million yuan, 93 million yuan, and 41 million yuan from 2021 to 2023 [5]. - In 2024, the company reported total revenue of 1.015 billion yuan, a slight decrease of 0.29%, and a net profit of 26.35 million yuan, down 35.84% year-on-year [5]. - The first quarter of 2025 showed a revenue increase of 24.24% to 291 million yuan, but net profit still declined by 16.13% [5]. Group 3: Stock Price Trends - Since its listing in 2016, Zhongya Co., Ltd.'s stock price has experienced significant volatility, peaking above 100 yuan before falling to as low as 4.34 yuan [6]. - As of July 22, 2025, the stock price was 8.86 yuan, reflecting a nearly 60% rebound since September 18, 2024 [7].

Core Viewpoint - The actual controller and several executives of Haigang Co., Ltd. plan to reduce their shareholdings due to personal financial needs, with a total reduction not exceeding 3% of the company's total share capital [1][5]. Shareholding Summary - Qian Liping, one of the actual controllers, holds a total of 10,540,838 shares (10.1004% of total share capital) and plans to reduce her holdings by up to 3,120,000 shares (2.9896%) within three months starting from 15 trading days after the announcement [1][2]. - The total shareholding of the actual controllers and their concerted actions amounts to 32,939,000 shares (31.5626% of total share capital) [2]. Reduction Plans of Executives - Executive Qian Xiaoda plans to reduce his indirect holdings by up to 45,000 shares (0.0431%) [3][7]. - Financial Director Li Jian plans to reduce his indirect holdings by up to 39,000 shares (0.0374%) [3][7]. - Vice General Manager Zhao Yubao plans to reduce his indirect holdings by up to 44,000 shares (0.0422%) [4][7]. - Vice General Manager Li Xin and Chairman of the Supervisory Board Jiang Wei each plan to reduce their indirect holdings by up to 40,000 shares (0.0383%) [4][7]. Financial Background - The shares being reduced were acquired before the company's initial public offering [5]. - As of March 31, 2025, Qian Liping is the fourth largest shareholder with 7,454,438 shares (7.14% of total share capital) [8]. - The company has not experienced a situation of breaking the net asset value or share price, and its cumulative cash dividends over the past three years have not been less than 30% of the average annual net profit [7].

Group 1 - The controlling shareholder, Changsha Zhengyuan Enterprise Management Co., Ltd., plans to reduce its holdings in Taijia Co., Ltd. by up to 7,552,126 shares, representing no more than 3.00% of the total share capital [1][2] - The reduction will occur through two methods: a maximum of 2,517,375 shares (1.00% of total share capital) via centralized bidding and up to 5,034,751 shares (2.00% of total share capital) through block trading [1][2] - As of the announcement date, Changsha Zhengyuan holds 58,897,350 shares, accounting for 23.40% of the total share capital, and the reduction will not affect the company's control or governance structure [2] Group 2 - The company raised a total of RMB 82,085.62 million from two fundraising events, with the first in 2017 raising RMB 17,620.00 million and the second in 2023 raising RMB 58,555.16 million [3][4][5] - In 2024, the company reported a revenue of RMB 1.73 billion, a decrease of 6.16% year-on-year, and a net profit attributable to shareholders of RMB 50.42 million, down 62.11% year-on-year [5][6] - For the first quarter of 2025, the company achieved a revenue of RMB 355.14 million, a decline of 20.00% compared to the same period last year, with a net profit of RMB 14.97 million, down 53.24% year-on-year [7]

Core Viewpoint - The controlling shareholder of Huason Pharmaceutical plans to reduce its stake again, indicating potential liquidity needs despite the company's stable fundamentals [1][3]. Group 1: Shareholder Reduction Plans - Chengdu Dijiang, the controlling shareholder, intends to reduce its holdings by up to 12.52 million shares, representing 3% of the total share capital, within three months from the announcement date [1]. - Executive Peng Xiaoyan also plans to sell up to 4,375 shares, which is 0.0010% of the total share capital [1]. - This marks the second reduction by the controlling shareholder within a year, with a previous reduction of the same amount completed between November 2024 and February 2025, resulting in proceeds of 14.7 million yuan [2]. Group 2: Company Performance - Huason Pharmaceutical reported a revenue of 775 million yuan in 2024, a year-on-year increase of 12.04%, and a net profit of 76.73 million yuan, up 134.66% [3]. - The growth is attributed to strong performance in traditional Chinese medicine products, with five exclusive Chinese patent medicines seeing a revenue increase of 21.71% [3]. - In Q1 2025, the company achieved a revenue of 239 million yuan, a 4.62% year-on-year growth, with net profits slightly increasing by 0.0098% [3][4]. Group 3: Market Dynamics - The revenue growth in Q1 2025 was slower due to a decrease in market demand compared to the previous year when flu cases were high, leading to increased sales of key products [4]. - Sales of the key product, Ganqi Bingmei Tablets, experienced a decline in revenue compared to the previous year, while other products like Liwei Anshen Capsules and Tongxie Ning Granules saw significant growth of 32.10% and 80.24%, respectively [4].